Pensionfund Sabic Sells 4,000 Shares of Johnson & Johnson $JNJ

Key Points

• Pensionfund Sabic has reduced its holdings in Johnson & Johnson by 14.7%, selling 4,000 shares and now maintaining 23,300 shares worth approximately $3.86 million.
• Institutional investors collectively own 69.55% of Johnson & Johnson's stock, with significant changes in positions from multiple funds during the first quarter.
• Wall Street analysts generally have a positive outlook, with an average target price of $176.29 and several upgrades from brokerages, reflecting confidence in the company’s growth potential.

Pensionfund Sabic decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.7% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 23,300 shares of the company's stock after selling 4,000 shares during the period. Johnson & Johnson comprises 1.2% of Pensionfund Sabic's portfolio, making the stock its 15th biggest position. Pensionfund Sabic's holdings in Johnson & Johnson were worth $3,864,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Nuveen LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $1,369,188,000. GAMMA Investing LLC raised its stake in shares of Johnson & Johnson by 24,450.4% during the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after purchasing an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after purchasing an additional 2,825,626 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $349,206,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on JNJ. Barclays upped their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Wall Street Zen upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Morgan Stanley increased their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Finally, Citigroup increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $178.10 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock's fifty day moving average price is $170.81 and its two-hundred day moving average price is $161.30. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The firm has a market cap of $428.93 billion, a price-to-earnings ratio of 19.05, a P/E/G ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the firm posted $2.82 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.